NCT03230318已完成2 期
A Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 148
- 试验地点
- 39
- 主要终点
- Substudy 1: Objective Response Rate (ORR)
研究概览
简要总结
This Phase II, open-label, single-arm study evaluated the anti-cancer activity of derazantinib in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) who received at least one prior regimen of systemic therapy. Patients received an oral once-daily total dose of 300 mg derazantinib capsules.
详细描述
This was a multi-center, open-label, single arm study which evaluated the anti-cancer activity of derazantinib in adult patients with inoperable or advanced iCCA in the following study population:
Patients with inoperable or advanced iCCA and with fibroblast growth factor receptor 2 (FGFR2) fusions (Substudy 1) or FGFR2 mutations/amplifications (Substudy 2), treated with at least one prior regimen of systemic therapy.
Derazantinib was supplied as 100 mg capsules. A dose of 300 mg once-daily (three capsules of 100 mg each) of derazantinib was administered orally to patients, 1 hour before, or 2 hours after, a meal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent granted prior to initiation of any study-specific procedures
- •18 years of age or older
- •Histologically or cytologically confirmed locally advanced, inoperable, or metastatic iCCA or mixed histology tumors
- •Substudy 1:
- •FGFR2 fusion status based on the following assessments:
- •a) If central laboratory was designated by Sponsor: Positive FISH test; and/or b) If non-central laboratory: i) Positive FISH or NGS test: patients were potentially enrolled and started dosing, but central confirmation was required* ii) Negative FISH or NGS test: tissue was submitted to the central laboratory designated by the Sponsor, and patients were only enrolled in case the central test was positive
- •*By used standard protocols and approved by local IRB/EC, by CLIA or other similar agency.
- •Substudy 2:
- •FGFR2 mutation/amplification status based on local NGS testing performed or commissioned by the respective study site.
- •Received at least one regimen of prior systemic therapy and then experienced documented radiographic progression
- •Measurable disease by RECIST version 1.1 criteria
- •ECOG performance status ≤ 1
- •Adequate organ functions as indicated by the following laboratory values (based on screening visit values from the central laboratory).
- •Hematological
- •Hemoglobin (Hgb) ≥ 9.0 g/dL
- •Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
- •Platelet count ≥ 75 x 109/L
- •International normalized ratio (INR) 0.8 to upper limit of normal (ULN) or ≤ 3 for subjects who received anticoagulant therapy such as Coumadin or heparin
- •Total bilirubin ≤ 2 x ULN
- •AST and ALT ≤ 3 ULN (≤ 5 x ULN for subjects with liver metastases)
- •Albumin ≥ 2.8 g/dL
- •Serum creatinine ≤ 1.5 x ULN
- •Creatinine clearance of ≥ 30 mL/min as estimated by the Cockcroft-Gault equation
- •Female and male patients of child-producing potential must had agreed to avoid becoming pregnant or impregnating a partner, respectively, used double-barrier contraceptive measures, oral contraception, or had to avoid of intercourse, during the study, and until at least 120 for 90 days after the last dose of derazantinib.
- •Male or female patients of child-producing potential must had agreed to comply with one of the following until at least 120 days after the last dose of derazantinib:
- •Abstinence from heterosexual activity
- •Using (or having their partner use) an acceptable method of contraception during heterosexual activity.
排除标准
- •Receipt of treatment before the first dose of study drug (Cycle 1 Day 1) within an interval shorter than the following, as applicable:
- •One chemotherapy or biological (e.g., antibody) cycle interval
- •Five half-lives of any small-molecule investigational or licensed medicinal product
- •Two weeks, for any investigational medicinal product with an unknown half-life
- •Four weeks of curative radiotherapy
- •Seven days of palliative radiotherapy
- •28 days of radiotherapy
- •Major surgery, locoregional therapy, or radiation therapy within four weeks of the first dose of derazantinib
- •Previous treatment with any FGFR inhibitor (e.g., Balversa® [erdafitinib], Pemazyre® [pemigatinib], infigratinib, rogaratinib, futibatinib, lenvatinib, ponatinib, dovitinib, nintedanib, AZD4547, LY2784455).
- •Patients who were unable or unwilling to swallow the complete daily dose of derazantinib capsules
- •Clinically unstable central nervous system (CNS) metastases (to be eligible, subjects must had stable disease ≥ 3 months, confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan, and/or had CNS metastases well controlled by low-dose steroids, anti-epileptics, or other symptom-relieving medications)
- •Evidence of clinically significant corneal or retinal disorder which was likely to increase the risk of eye toxicity, including but not limited to bullous/band keratopathy, keratoconjunctivitis (unless keratoconjunctivitis sicca), corneal abrasion, inflammation/ulceration, confirmed by ophthalmologic examination.
- •Uncontrolled or active hepatobiliary disorders, untreated or ongoing complications after laparoscopic procedures or stent placement, including but not limited to active cholangitis, biloma or abscess (to be eligible, the subjects had to be treated and disorders/complications should had been resolved within 2 weeks prior to the first dose of derazantinib)
- •History of significant cardiac disorders:
- •Myocardial infarction (MI) or congestive heart failure defined as Class II to IV per the New York Heart Association (NYHA) classification within 6 months of the first dose of derazantinib (MI that occurred > 6 months prior to the first dose of derazantinib was permitted)
- •QTcF >450 msec (males or females)
- •Serum electrolyte abnormalities defined as follows:
- •Hyperphosphataemia: Serum phosphate > institutional ULN
- •Hyperkalemia: > 6.0 mmol/L
- •Hypokalemia: < 3.0 mmol/L
- •Hypercalcemia: corrected serum calcium < 1.75 mmol/L (< 7.0 mg/dL)
- •Hypocalcemia: corrected serum calcium > 3.1 mmol/L (> 12.5 mg/dL)
- •Hypomagnesemia: < 0.4 mmol/L (< 0.9 mg/dL)
- •Significant gastrointestinal disorder(s) that could had, in the opinion of the Investigator, interfered with the absorption, metabolism, or excretion of derazantinib (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)
- •History of additional malignancy that was progressing or required active treatment. Exceptions included basal cell carcinoma of the skin, squamous cell carcinoma of the skin that had undergone potentially curative therapy, and in situ cervical cancer.
- •Uncontrolled illness not related to cancer, including but not limited to:
- •Psychiatric illness/substance abuse/social situation that would limit compliance with study requirements
- •Known uncontrolled human immunodeficiency virus (HIV) infection
- •Severe bacterial, fungal, viral and/or parasitic infections on therapeutic oral or IV medication at the time of first dose of study drug administration
- •Blood or albumin transfusion within 5 days of the blood draw which has been used to confirm eligibility
- •Pregnant or breast feeding
- •Known hypsersensitivity to derazantinib, or to any of the study drug excipients (starch, lactose, crospovidone, magnesium stearate)
研究组 & 干预措施
derazantinib
Experimental
Oral administration
干预措施: derazantinib (Drug)
结局指标
主要结局
Substudy 1: Objective Response Rate (ORR)
时间窗: From first dose and up to 54 months
ORR was defined as the proportion of patients who achieved a confirmed clinical response (CR) or partial response (PR) by blinded independent central review using the internationally recognized criteria for the radiological assessment in tumor response of solid tumors (RECIST) Version 1.1
Substudy 2: Progression Free Survival at 3 Months (PFS 3)
时间窗: From first dose and up to 3 months
PFS3 was defined as the proportion of patients who have progression-free survival at 3 months from the first date of receiving study drug as assessed by survival status and blinded independent central review as per RECIST 1.1.
次要结局
- PFS(From first dose and up to 54 months)
- Duration of Response (DoR)(From first dose and up to 54 months)
- Overall Survival (OS)(From first dose and up to 54 months)
- Substudy 2: Objective Response Rate(From first dose and up to 54 months)
- Number of Patients With Grade 3-5 Treatment-emergent Adverse Events (TEAEs)(TEAEs were defined as all events occurring after drug treatment began and up to 30 days after last study drug administration)
研究者
研究点 (39)
Loading locations...
相似试验
已完成
1 期
Derazantinib and Atezolizumab in Patients With Urothelial CancerUrothelial CarcinomaNCT04045613Basilea Pharmaceutica95
终止
1 期
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric AdenocarcinomaGastric AdenocarcinomaNCT04604132Basilea Pharmaceutica47
进行中（未招募）
1 期
A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrationsEUCTR2019-004505-27-DEBasilea Pharmaceutica International Ltd., Allschwil314
进行中（未招募）
1 期
A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrationsEUCTR2019-004505-27-BEBasilea Pharmaceutica International Ltd, Allschwil314
进行中（未招募）
1 期
A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrationsEUCTR2019-004505-27-GBBasilea Pharmaceutica International Ltd.254